about
Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled TrialsInflammatory Bowel Disease Cohort Studies in Korea: Present and FutureIndicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United StatesCommunication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician VisitsKey Questions for Translation of FFA Receptors: From Pharmacology to Medicines.Update on the Use of Biologic Therapy in Ulcerative Colitis.Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.Coordinated Hospital-Home Fecal Microbiota Transplantation via Percutaneous Endoscopic Cecostomy for Recurrent Steroid-Dependent Ulcerative ColitisUnderstanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative ColitisPatients' Preference for a Specific Anti-Tumor Necrosis Factor Agent: Korea versus Western.Does the Cyclosporine Still Have a Potential Role in the Treatment of Acute Severe Steroid-Refractory Ulcerative Colitis?Anti-inflammatory, antioxidant and anti-apoptotic activity of diosmin in acetic acid-induced ulcerative colitis.Molecular topology: a strategy to identify novel compounds against ulcerative colitis.Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease.Immunogenicity of biologics in inflammatory bowel disease.Effect of roxithromycin on mucosal damage, oxidative stress and pro-inflammatory markers in experimental model of colitis.Altered Prostasin (CAP1/Prss8) Expression Favors Inflammation and Tissue Remodeling in DSS-induced Colitis.The application of molecular topology for ulcerative colitis drug discovery.The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis.Colon-targeted delivery of cyclosporine A using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis.
P2860
Q28070298-1F0F159E-BF58-4B11-8D28-5AC8E6CD07F2Q28087662-3DE4738C-8534-49FF-883F-F4347FDC61D0Q33584629-B3296E4F-2DFC-4711-AA4C-1154C6E57175Q33866413-976FAC06-BB87-4059-A0BF-EEA1688395ECQ39016250-537D287F-4DEC-43A7-8F29-ACB0E1D16608Q39102244-81E971E3-EE1E-4A25-AEB6-17450D88BB18Q39306418-14167A35-A3FB-4BC1-AD83-598FA0AC303FQ41629385-DD95BA6B-09BD-4FDD-B01A-7ED8A5A41C2DQ42651996-8ADFBEB1-6C87-4657-818C-C3D9AA14022DQ42849845-131F2A37-FD28-4F56-A4F7-A3C3C81A2008Q43139980-CCDE199C-CADA-4959-BFE4-B76E88E23605Q46236112-5AAFECA9-4006-428D-AF06-625A7FAA6858Q48304854-09F89583-5D32-4FA0-AE42-54A8113A3EEBQ49315243-538D95AC-ADDA-4733-B8F5-842F6FF94F11Q49404676-4824E678-41FA-40AC-BFC1-2A58A1490118Q49500932-C82E44CC-DC2E-498B-BAA0-0DC95BE5AE1BQ51379981-08CC369F-6DE7-4279-A6E9-D6734C8717DDQ52448502-B0A9B2DE-CCBA-4F18-BC37-7E867C0F9B4AQ53451864-7C513654-59F6-412A-87C2-D9296FE9DECDQ55113137-55BCBFD8-42F5-4182-8EDC-C7AB0CA501CE
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Current and emerging biologics for ulcerative colitis.
@ast
Current and emerging biologics for ulcerative colitis.
@en
Current and emerging biologics for ulcerative colitis.
@nl
type
label
Current and emerging biologics for ulcerative colitis.
@ast
Current and emerging biologics for ulcerative colitis.
@en
Current and emerging biologics for ulcerative colitis.
@nl
prefLabel
Current and emerging biologics for ulcerative colitis.
@ast
Current and emerging biologics for ulcerative colitis.
@en
Current and emerging biologics for ulcerative colitis.
@nl
P2860
P356
P1433
P1476
Current and emerging biologics for ulcerative colitis.
@en
P2093
Sung Chul Park
Yoon Tae Jeen
P2860
P356
10.5009/GNL14226
P5008
P577
2015-01-01T00:00:00Z